UWillow Bark

-Delile

• Kungenzeka kusebenze ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

Amagxolo eWillow amagxolo avela ezinhlotsheni ezahlukahlukene zesihlahla somnyezane, kufaka phakathi umngcunube omhlophe noma i-willow yaseYurophu, i-black willow noma i-pussy willow, i-crack willow, i-willow e-purple, nabanye. Amagxolo asetshenziselwa ukwenza umuthi.

Amagxolo eWillow enza okuningi njenge-aspirin. Isetshenziselwa kakhulu ubuhlungu nomkhuhlane. Kepha abukho ubufakazi obuhle besayensi obukhombisa ukuthi busebenza njenge-aspirin yalezi zimo.

Isifo seCoronavirus 2019 (COVID-19): Abanye ochwepheshe baxwayisa ngokuthi amagxolo omnyezane angaphazamisa impendulo yomzimba uma ubhekene ne-COVID-19. Ayikho idatha eqinile yokuxhasa lesi sexwayiso. Kepha futhi akukho datha enhle yokuxhasa usebenzisa amagxolo e-willow e-COVID-19.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze UWILLOW BARK zimi kanje:

Kungenzeka kusebenze ...

• Ukuhlungu obusemhlane. Amagxolo eWillow abonakala enciphisa izinhlungu ezisezingeni eliphansi. Ukweqiwa okuphezulu kubonakala kusebenza kakhulu kunamanani aphansi. Kungathatha kuze kube yisonto ukwenza ngcono okukhulu.

Ubufakazi obanele bokukala ukusebenza kwe ...

• I-osteoarthritis. Ukucwaninga ngokukhishwa kwe-willow bark kwe-osteoarthritis kuveze imiphumela ephikisanayo. Olunye ucwaningo lukhombisa ukuthi lunganciphisa ubuhlungu be-osteoarthritis. Eqinisweni, kunobunye ubufakazi obuphakamisa ukuthi ukukhishwa kwe-willow bark kusebenza kanye nemithi ejwayelekile ye-osteoarthritis. Kepha olunye ucwaningo alukhombisi nzuzo.
• Isifo samathambo (RA). Ucwaningo lokuqala lubonisa ukuthi ukukhishwa kwe-willow bark akubunciphisi ubuhlungu kubantu abane-RA.
• Uhlobo lwe-arthritis oluthinta kakhulu umgogodla (i-ankylosing spondylitis).
• Umkhuhlane ovamile.
• Imfiva.
• Umkhuhlane (umkhuhlane).
• Gout.
• Ubuhlungu bekhanda.
• Ubuhlungu obuhlangene.
• Izikhukhula zokuya esikhathini (i-dysmenorrhea).
• Ubuhlungu bemisipha.
• Ukukhuluphala ngokweqile.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala ukusebenza kwegxolo lomnyezane kulokhu kusetshenziswa.

Amagxolo eWillow aqukethe ikhemikhali ebizwa ngokuthi i-salicin efana ne-aspirin.

Lapho ithathwa ngomlomo: Amagxolo eWillow OKUNGENZEKA UKUPHEPHA kubantu abaningi abadala lapho bethathwe kuze kube amasonto ayi-12. Kungadala ikhanda elibuhlungu, ukucasuka kwesisu, kanye nohlelo lokugaya ukudla. Kungadala futhi ukulunywa, ukuqubuka, kanye nokusabela kokungezwani komzimba, ikakhulukazi kubantu abaphikisana ne-aspirin.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa: Alukho ulwazi olwanele olunokwethenjelwa ukwazi ukuthi amagxolo e-willow aphephile yini ukuwasebenzisa lapho ukhulelwe. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Ukuncelisa ibele: Kusetshenziswa amagxolo omnyezane ngenkathi ukuncelisa ibele MHLAWUMBI ANGIPHEPHILE. Amagxolo eWillow aqukethe amakhemikhali angangena obisini lwebele futhi abe nemiphumela eyingozi enganeni esancelayo. Ungayisebenzisi uma uncelisa ibele.

Izingane: Amagxolo eWillow MHLAWUMBI ANGIPHEPHILE n izingane lapho zithathwa ngomlomo ukuze zithelele izifo ezinjengemikhuhlane nomkhuhlane. Kukhona okunye ukukhathazeka ukuthi, njenge-aspirin, kungakhuphula ubungozi bokuthola i-Reye's syndrome. Hlala ohlangothini oluphephile futhi ungasebenzisi amagxolo e-willow ezinganeni.

Izinkinga zokopha: Amagxolo eWillow angandisa ingozi yokuphuma kwegazi kubantu abanezinkinga zokopha.

Isifo sezinso: Amagxolo eWillow anganciphisa ukugeleza kwegazi ngezinso. Lokhu kungaholela ekuhlulekeni kwezinso kwabanye abantu. Uma unesifo sezinso, ungasebenzisi amagxolo e-willow.

Ukuzwela ku-aspirin: Abantu abane-ASTHMA, IZILONDA ZESisu, ISIFO SIKASHUKELA, I-GOUT, I-HEMOPHILIA, I-HYPOPROTHROMBINEMIA, noma i-KIDNEY noma i-LIVER ISIFO bangazwela ku-aspirin kanye ne-willow bark. Ukusebenzisa amagxolo e-willow kungadala ukusabela okweqile komzimba. Gwema ukusebenzisa.

Ukuhlinzwa: Amagxolo eWillow angahle anciphise ukuvaleka kwegazi. Kukhona ukukhathazeka okungadala ukopha okwengeziwe ngesikhathi nangemva kokuhlinzwa. Yeka ukusebenzisa amagxolo omnyezane okungenani amasonto amabili ngaphambi kokuhlinzwa okuhleliwe.

Okukhulu

Ungathathi le nhlanganisela.

Imithi eyehlisa ukunqamuka kwegazi (Anticoagulant / Antiplatelet drug)

Amagxolo eWillow angahle anciphise ukuvimba kwegazi. Ukuthatha amagxolo e-willow kanye nemithi epholisa nokuvimba kwegazi kungakhuphula amathuba okulimala nokopha.

Eminye imishanguzo eyehlisa ijubane ukuvala igazi ifaka phakathi i-aspirin, i-clopidogrel (i-Plavix), i-diclofenac (i-Voltaren, i-Cataflam, abanye), i-ibuprofen (i-Advil, i-Motrin, abanye), i-naproxen (i-Anaprox, i-Naprosyn, abanye), i-dalteparin (i-Fragmin), i-enoxaparin (i-Lovenox) , heparin, warfarin (Coumadin), nabanye.

Maphakathi

Qaphela ngale nhlanganisela.

I-Acetazolamide

Amagxolo eWillow aqukethe amakhemikhali angakhuphula inani le-acetazolamide egazini. Ukuthatha amagxolo e-willow kanye ne-acetazolamide kungakhuphula imiphumela kanye nemiphumela emibi ye-acetazolamide.

I-Aspirin

Amagxolo eWillow aqukethe amakhemikhali afana ne-aspirin. Ukuthatha amagxolo e-willow kanye ne-aspirin kungakhuphula imiphumela kanye nemiphumela emibi ye-aspirin.

I-Choline Magnesium Trisalicylate (Trilisate)

Amagxolo eWillow aqukethe amakhemikhali afana ne-choline magnesium trisalicylate (Trilisate). Ukuthatha amagxolo e-willow kanye ne-choline magnesium trisalicylate (Trilisate) kungakhuphula imiphumela kanye nemiphumela emibi ye-choline magnesium trisalicylate (Trilisate).

I-Salsalate (Disalcid)

I-Salsalate (Disalcid) uhlobo lomuthi obizwa nge-salicylate. Iyafana ne-aspirin. Amagxolo eWillow aqukethe ne-salicylate efana ne-aspirin. Ukuthatha i-salsalate (Disalcid) kanye namagxolo e-willow kungakhuphula imiphumela kanye nemiphumela emibi ye-salsalate (Disalcid).

Amakhambi nezengezo ezinganciphisa ukujiya kwegazi

Amagxolo eWillow anganciphisa ukujiya kwegazi. Ukuyisebenzisa kanye namanye amakhambi anganciphisa nokuqina kwegazi kungakhuphula amathuba okuphuma kwegazi nokulimala kwabanye abantu. Lawa makhambi afaka i-clove, i-danshen, i-garlic, i-ginger, i-ginkgo, i-ginseng, i-meadowsweet, i-red clover, namanye.

Amakhambi aqukethe amakhemikhali afana ne-aspirin (ama-salicylates)

Amagxolo eWillow aqukethe ikhemikhali elifana nekhemikhali elifana ne-aspirin elibizwa ngokuthi i-salicylate. Ukuthatha amagxolo e-willow kanye namakhambi aqukethe i-salicylate kungakhuphula imiphumela ye-salicylate kanye nemiphumela emibi. Amakhambi aqukethe i-salicylate afaka i-aspen bark, i-black haw, i-poplar, ne-meadowsweet.

Akukho ukuxhumana okwaziwayo nokudla.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

NGOMLOMO:

• Ngezinhlungu emuva: Kusetshenziswe i-Willow bark okuhlinzeka ngo-120-240 mg salicin. Umthamo ophakeme we-240 mg ungasebenza kangcono.

Basket Willow, Bay Willow, Black Willow, Black Willow Extract, Brittle Willow, Corteza de Sauce, Crack Willow, Daphne Willow, Écorce de Saule, Écorce de Saule Blanc, European Willow, European Willow Bark, Extrait d'Écorce de Saule, Extrait d'Écorce de Saule Blanc, Extrait de Saule, Extrait de Saule Blanc, Knackweide, Laurel Willow, Lorbeerweide, Organic Willow, Osier Blanc, Osier Rouge, Purple Osier, Purple Osier Willow, Purple Willow, Purpurweide, Pussy Willow, Reifweide, Salifiya Cortex, Salix alba, Salix babylonica, Salix daphnoides, Salix fragilis, Salix nigra, Salix pentandra, Salix purpurea, Saule, Saule Argenté, Saule Blanc, Saule Commun, Saule des Viviers, Saule Discolore, Saule Freile, Saule Noir, Saule Noir, Silberweide, Violet Willow, Weidenrinde, White Willow, White Willow Bark, Willowbark, White Willow Khipha, Willow Bark Khipha.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. UWuthold K, Germann I, Roos G, et al. I-chromatography enezingqimba ezincane kanye nokuhlaziywa kwedatha ye-multivariate kokukhishwa kwe-willow bark. UJ Chromatogr Sci. 2004; 42: 306-9. Buka okungaqondakali.
2. Uehleke B, Müller J, Stange R, Kelber O, Melzer J. Willow bark bakhipha i-STW 33-I ekwelapheni isikhathi eside kweziguli ezinezinhlungu zamathambo ikakhulu i-osteoarthritis noma ubuhlungu beqolo. I-Phytomedicine. 2013 Aug 15; 20: 980-4. Buka okungaqondakali.
3. I-Beer AM, i-Wegener T. Willow bark ekhishwe (i-Salicis cortex) ye-gonarthrosis ne-coxarthrosis - imiphumela yocwaningo lwamaqoqo neqembu elilawulayo. I-Phytomedicine. 2008 Nov; 15: 907-13. Buka okungaqondakali.
4. I-Nieman DC, i-Shanely RA, i-Luo B, i-Dew D, i-MP ye-Meaney, u-Sha W. Isengezo sokuthengisa esidayiswayo sidambisa izinhlungu ezihlangene kubantu abadala bomphakathi: icala lomphakathi elilawulwa izimpumputhe, elilawulwa yi-placebo Umsoco J 2013; 12: 154. Buka okungaqondakali.
5. UGagnier JJ, VanTulder MW, Berman B, no-al. Umuthi we-Botanical wezinhlungu ezisezingeni eliphansi: ukubuyekeza okuhlelekile [i-abstract]. I-9th Annual Symposium on Complementary Health Care, Disemba 4th-6th, Exter, UK 2002.
6. UWerner G, uMarz RW, noSchremmer D. Assalix wezinhlungu ezingapheli zomqolo ongaphakeme kanye ne-arthralgia: ukuhlaziywa kwesikhashana kwesifundo sokubhekwa kokukhangisa okuthunyelwe. I-Symposium Yonyaka Yesishiyagalombili Yokunakekelwa Kwezempilo Okuhambisanayo, 6 - 8 Disemba 2001 2001.
7. I-CV Encane, iParsons T, neLogan S. Ukwelashwa ngamakhambi ekwelapheni i-osteoarthritis. Umtapo Wezincwadi WaseCochrane 2002; 1.
8. I-Loniewski I, i-Glinko A, ne-Samochowiec L. Ukukhishwa kwe-willow okwenziwe okujwayelekile: isidakamizwa esinamandla sokulwa nokuvuvukala. I-Symposium Yonyaka Yesishiyagalombili Yokunakekelwa Kwezempilo Okuhambisanayo, ngomhla ka-6 kuya ku-8 kuDisemba 2001.
9. Schaffner W. Eidenrinde-ein antiarrheumatikum der modernen iPhytotherapie? 1997; 125-127.
10. UBlack A, uKünzel O, uChrubasik S, no-al. Ezomnotho zokusebenzisa amagxolo e-willow zikhipha ekwelapheni iziguli okwelashwa ubuhlungu obuphansi emuva [abstract]. I-Symposium Yonyaka Yesishiyagalombili Yokunakekelwa Kwezempilo Okuhambisanayo, ngomhla ka-6 kuya ku-8 kuDisemba 2001.
11. UChrubasik S, uKünzel O, uModeli A, no-et al. I-Assalix® vs. Vioxx® yezinhlungu ezisezingeni eliphansi - isifundo esilawulwa ngokungahleliwe. I-Symposium Yonyaka Yesishiyagalombili Yokunakekelwa Kwezempilo Okuhambisanayo, 6 - 8 Disemba 2001 2001.
12. UMeier B, uShao Y, uJulkunen-Tiitto R, no-al. Ucwaningo lwe-chemotaxonomic lwama-phenolic compounds ezinhlotsheni ze-willow zaseSwitzerland. UPlanta Medica 1992; 58 (isisekelo 1): A698.
13. UHyson MI. Isifihla-buso se-anticephalgic photoprotective preedicated. Umbiko wesifundo esilawulwa ngempumelelo esiyimpumputhe esilawulwa nge-placebo sokwelapha okusha kwekhanda elibuhlungu obuhambisana ne-frontalis ne-photophobia. Izinwele 1998; 38: 475-477.
14. USteinegger, E. noHovel, H. [Ucwaningo lwe-Analytic kanye ne-biologic ngezinto ze-Salicaceae, ikakhulukazi ku-salicin. II. Ucwaningo lwezinto eziphilayo]. I-Pharm Acta Helv. Ngo-1972; 47: 222-234. Buka okungaqondakali.
15. Sweeney, K. R., Chapron, D. J., Brandt, J. L., Gomolin, I.H, Feig, P. U., noKramer, P. A.Ukuxhumana okunobuthi phakathi kwe-acetazolamide ne-salicylate: imibiko yamacala kanye nencazelo ye-pharmacokinetic. I-Clin Pharmacol Ther 1986; 40: 518-524. Buka okungaqondakali.

16. Moro PA, Flacco V, Cassetti F, Clementi V, Colombo ML, Chiesa GM, Menniti-Ippolito F, Raschetti R, Santuccio C. Hypovolemic ukushaqeka ngenxa yokopha okukhulu kwamathumbu enganeni ethatha isiraphu yamakhambi. U-Ann Ist Super Sanita. 2011; 47: 278-83.

    
    
    Buka okungaqondakali.
17. UCameron, M., Gagnier, J. J., Little, C. V., Parsons, T. J., Blumle, A., noChrubasik, S. Ubufakazi bokusebenza kwemikhiqizo yemithi yokwelapha ekwelapheni i-arthritis. Ingxenye I: I-Osteoarthritis. I-Phytother.I-2009; 23: 1497-1515. Buka okungaqondakali.

18. UKenstaviciene P, Nenortiene P, Kiliuviene G, Zevzikovas A, Lukosius A, Kazlauskiene D. Ukusetshenziswa kwe-high-performance liquid chromatography yocwaningo lwe-salicin kumagxolo ezinhlobonhlobo ze-Salix. IMedicina (Kaunas). U-2009; 45: 644-51.

    Buka okungaqondakali.

19. UVlachojannis JE, uCameron M, uChrubasik S. Ukubuyekezwa okuhlelekile kokusebenza kwegxolo lomnyezane lobuhlungu bemisipha. I-Phytother Res. 2009 Julayi; 23: 897-900.

    Buka okungaqondakali.

20. UNahrstedt A, uSchmidt M, uJäggi R, uMetz J, uKhayyal MT. Ukukhishwa kwe-Willow bark: umnikelo wama-polyphenols kuwo wonke umphumela. I-Wien Med Wochenschr. 2007; 157 (13-14): 348-51.

    Buka okungaqondakali.
21. Khayyal, M. T., El Ghazaly, M. A., Abdallah, D. M., Okpanyi, S. N., Kelber, O., noWeiser, D. Izindlela ezibandakanyeka kumphumela wokulwa nokuvuvukala wokukhishwa okujwayelekile kwe-willow bark. I-Arzneimittelforschung 2005; 55: 677-687. Buka okungaqondakali.
22. UKammerer, B., Kahlich, R., Biegert, C., Gleiter, C.H, noHeide, L. HPLC-MS / MS bahlaziya izicucu zamagatsha omngcunube aqukethwe kumalungiselelo okwenziwa kwemithi. I-Phytochem Anal. 2005; 16: 470-478. Buka okungaqondakali.
23. UClauson, K. A., Santamarina, M. L., Buettner, C. M., noCauffield, J. S. Ukuhlolwa kobukhona bezexwayiso ezihlobene ne-aspirin namagxolo e-willow. U-Ann Pharmacother. 2005; 39 (7-8): 1234-1237. Buka okungaqondakali.
24. U-Akao, T., Yoshino, T., Kobashi, K., noHattori, M. Ukuhlolwa kwe-salicin njenge-antipyretic prodrug engabangeli ukulimala esiswini. UPlanta Med 2002; 68: 714-718. Buka okungaqondakali.
25. UChrubasik, S., Kunzel, O., Omnyama, A., uConradt, uC., NoKerschbaumer, F. Umthelela ongaba khona kwezomnotho wokusebenzisa ukukhishwa kwe-willow bark ekhishwe ekwelapheni iziguli ezisezingeni eliphansi: isifundo esivulekile esingahleliwe. I-Phytomedicine 2001; 8: 241-251. Buka okungaqondakali.

26. I-CV Encane, iParsons T. Ukwelashwa ngamakhambi ekwelapheni i-osteoarthritis. ICochrane Database Syst Rev. 2001;: CD002947.

    Buka okungaqondakali.
27. UChrubasik, J. E., Roufogalis, B. D., noChrubasik, S. Ubufakazi bokusebenza kwemithi yamakhambi eqeda ukuvuvukala ekwelapheni i-osteoarthritis ebuhlungu kanye nobuhlungu obungapheli obuya emuva. I-Phytother Res 2007; 21: 675-683. Buka okungaqondakali.
28. UGagnier, J. J., van Tulder, M., Berman, B., noBombardier, C. Umuthi wamakhambi wezinhlungu ezisezingeni eliphansi. Idatha yedatha yeCochrane. 2006; CD004504. Buka okungaqondakali.
29. I-Mills SY, i-Jacoby RK, i-Chacksfield M, i-Willoughby M. Umphumela wemithi yamakhambi ephathekayo ekusizeni ubuhlungu obungapheli besifo samathambo: isifundo esiyimpumputhe. UBr J Rheumatol 1996; 35: 874-8. Buka okungaqondakali.
30. U-Ernst, E. noChrubasik, S. Phyto-anti-inflammatories. Ukubuyekezwa okuhlelekile kokuhlolwa okungahleliwe, okulawulwa yi-placebo, okuyimpumputhe kabili. I-Rheum.Dis Clin North eNyakatho Am 2000; 26: 13-27, vii. Buka okungaqondakali.
31. UGagnier JJ, van Tulder MW, Berman B, Bombardier C.Umuthi wamakhambi wezinhlungu ezisezingeni eliphansi. Ukubuyekezwa kukaCochrane. Isiphetho 2007; 32: 82-92. Buka okungaqondakali.
32. I-Fiebich BL, i-Appel K. Imiphumela elwa nokuvuvukala yokukhishwa kwe-willow bark. Umtholampilo Pharmacol Ther 2003; 74: 96. Buka okungaqondakali.
33. ICoffey CS, uSteiner D, uB Baker BA, u-Allison DB. Isilingo somtholampilo esilawulwa ngokungahleliwe somkhiqizo oqukethe i-ephedrine, i-caffeine, nezinye izithako ezivela emithonjeni yamakhambi ekwelapheni ukukhuluphala ngokweqile nokukhuluphala ngokungabikho kwendlela yokuphila. I-Int J Obes Relat Metab Disord 2004; 28: 1411-9. Buka okungaqondakali.
34. UKrivoy N, uPavlotzky E, uChrubasik S, et al. Umphumela wokukhishwa kwe-salicis cortex ekuhlanganisweni kweplatelet yabantu. UPlanta Med 2001; 67: 209-12. Buka okungaqondakali.
35. UWagner I, uGreim C, uLaufer S, et al. Umthelela wokukhishwa kwe-willow bark emsebenzini we-cyclooxygenase naku-tumor necrosis factor alpha noma i-interleukin 1 beta release in vitro and ex vivo. I-Clin Pharmacol Ther 2003; 73: 272-4. Buka okungaqondakali.
36. USchmid B, uKotter I, uHeide L. Pharmacokinetics we-salicin ngemuva kokuphathwa ngomlomo kokukhishwa okwenziwe ngamagxolo e-willow. I-Eur J Clin Pharmacol. 2001; 57: 387-91. Buka okungaqondakali.
37. Isifo sezinso sikaSchwarz A. Beethoven sisuselwa ku-autopsy yakhe: icala le-papillary necrosis. NginguJ J Kidney Dis 1993; 21: 643-52. Buka okungaqondakali.
38. I-D'Agati V. Ngabe i-aspirin idala ukwehluleka okunamandla noma okungamahlalakhona kwezinso ezilwaneni zokuhlola nakubantu? U-Am J Kidney Dis 1996; 28: S24-9. Buka okungaqondakali.
39. UChrubasik S, Kunzel O, Model A, et al. Ukwelashwa kobuhlungu obuphansi emuva nge-herbal noma i-synthetic anti-rheumatic: isifundo esilawulwa ngokungahleliwe. Amagxolo eWillow akhipha izinhlungu ezisezingeni eliphansi. I-Rheumatology (Oxford) 2001; 40: 1388-93. Buka okungaqondakali.
40. UClark JH, uWilson WG. Usana olunezinsuku eziyi-16 olunceliswa nge-metabolic acidosis olubangelwa yi-salicylate. Clin Pediatr (Phila) 1981; 20: 53-4. Buka okungaqondakali.
41. Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR.Amazinga weSalum salicylate osaneni oluncelisiwe. U-Ann Rheum Dis 1987; 46: 638-9. Buka okungaqondakali.
42. Ukuphathwa Kwezokudla Nezidakamizwa, i-HHS. Ukufaka ilebula ngemikhiqizo yezidakamizwa yomlomo noma engxenyeni ethengiswayo equkethe ama-aspirin nama-nonicirin salicylates; Isexwayiso seReye’s Syndrome. Umthetho wokugcina. Ukubhaliswa Kwezezimali 2003; 68: 18861-9. Buka okungaqondakali.
43. I-Fiebich BL, i-Chrubasik S. Imiphumela yokukhishwa kwe-salix ethanolic ekukhishweni kwabalamuli abavuthayo abakhethiwe ku-vitro. I-Phytomedicine 2004; 11: 135-8. Buka okungaqondakali.
44. UBiegert C, uWagner I, uLudtke R, et al. Ukusebenza nokuphepha kwe-willow bark ekhishwe ekwelapheni i-osteoarthritis ne-rheumatoid arthritis: imiphumela yezilingo ezimbili ezilawulwa ngokungahleliwe ezilawulwa kabili. UJ Rheumatol 2004; 31: 2121-30. Buka okungaqondakali.
45. USchmid B, uLudtke R, uSelbmann HK, et al. Ukusebenza nokubekezeleleka kokukhishwa komgogodla okulinganiselwe kukhishwe kwiziguli ezine-osteoarthritis: i-placebo elawulwa ngokungahleliwe, isilingo somtholampilo esiyimpumputhe. I-Phytother Res 2001; 15: 344-50. Buka okungaqondakali.
46. IBoullata JI, McDonnell PJ, i-CD ye-Oliva. Ukusabela kwe-Anaphylactic kokungezelelweyo kokudla okuqukethe amagxolo e-willow. I-Ann Pharmacother 2003; 37: 832-5 .. Buka okungaqondakali.
47. Ukuphathwa Kwezokudla Nezidakamizwa, i-HHS. Umthetho wokugcina omemezela izengezo zokudla eziqukethe i-ephedrine alkaloids engcolisiwe ngoba ziveza ingozi engenangqondo; Umthetho wokugcina. Ukubhaliswa Kwezezimali 2004; 69: 6787-6854. Buka okungaqondakali.
48. UDulloo AG, uMiller DS. I-Ephedrine, i-caffeine ne-aspirin: izidakamizwa "ezingaphezulu kwekhawunta" ezisebenzisanayo ukukhuthaza i-thermogenesis kokukhuluphala. Ukudla okunomsoco 1989; 5: 7-9.
49. UChrubasik S, Eisenberg E, Balan E, et al. Ukwelashwa kokukhula kobuhlungu obuphansi emuva ngokukhishwa kwe-willow bark: isifundo esingahleliwe esiyimpumputhe. NginguJ J 2000; 109: 9-14. Buka okungaqondakali.
50. UDulloo AG, uMiller DS. I-Aspirin njengomgqugquzeli we-ephedrine-induced thermogenesis: ukusetshenziswa okungaba khona ekwelapheni ukukhuluphala. Ngingu-J J Nutriti 1987; 45: 564-9. Buka okungaqondakali.
51. IHorton TJ, uGeissler CA. I-Aspirin inika amandla umphumela we-ephedrine empendulweni ye-thermogenic ekudleni kwabesifazane abakhuluphele kepha hhayi abancikile. I-Int J Obes 1991; 15: 359-66. Buka okungaqondakali.

Kugcine ukubuyekezwa - 01/28/2021